Evaluation of Clinical Characteristics and Outcome of COVID19 Pneumonia in Assiut University Hospital

Evaluation of Clinical Characteristics and Outcome of COVID19 Pneumonia in Assiut

• Evaluation of the clinical presentation of COVID 19 pneumonia.
• Identification the risk factors of severing COVID 19 pneumonia.
• Evaluation of the outcome of the disease.

Study Overview

• Status: Unknown
• Conditions: Coronavirus
• Intervention / Treatment: Device: CT of the chest

Detailed Description

Coronavirus disease 2019 (COVID-19) is defined as illness caused by a novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; formerly called 2019-nCoV), which was first identified amid an outbreak of respiratory illness cases in Wuhan City, Hubei Province, China. It was initially reported to the WHO on December 31, 2019. On January 30, 2020, the WHO declared the COVID-19 outbreak a global health emergency.On March 11, 2020, the WHO declared COVID-19 a global pandemic, its first such designation since declaring H1N1 influenza a pandemic in 2009. The incubation period for coronavirus disease 2019 (COVID-19) is believed to extend to 14 days, with a median time of 4-5 days from exposure to symptomatic onset. In one study, 97.5% of symptomatic patients developed symptoms within 11.5 days of becoming infected. Most patients with coronavirus disease 2019 (COVID-19) will experience the following (in descending frequency): Fever, Cough, Fatigue, Anorexia, Shortness of breath, Sputum production, Myalgia.

Atypical presentations have been described, and older adults and persons with medical comorbidities may have delayed presentation of fever and respiratory symptoms.

Less common symptoms (< 10%) include headache, confusion, rhinorrhea, sore throat, and hemoptysis. Some patients have experienced gastrointestinal symptoms such as diarrhoea and nausea prior to developing fever and lower respiratory tract signs and symptoms. anosmia may precede the onset of respiratory symptoms. The most common serious manifestation of COVID-19 upon the initial presentation is pneumonia. Fever, cough, dyspnea, and abnormalities on chest imaging are common in these cases. Bilateral distribution of ground-glass opacities (GGO) with or without consolidation in posterior and peripheral lungs was the cardinal hallmark of COVID-19. However, with further analysis of increasing cases, a diversity of interesting CT imaging features were found, including crazy paving pattern, airway changes, halo sign, Pleural changes including pleural thickening and pleural effusion, Vascular enlargement, Air bubble sign, Lymphadenopathy, etc, which may shed light on the possible mechanism of lung injury in COVID-19. On the laboratory aspect leukopenia, leukocytosis, and lymphopenia were common among early cases. Lactate dehydrogenase and ferritin levels are commonly elevated.

• Study Type: Observational
• Enrollment (Anticipated): 100

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 99 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

200 patients diagnosed as COVID19 pneumonia and eligible for search criteria

Description

Inclusion Criteria:

• Patients with COVID 19 PCR positive

Exclusion Criteria:

• Patients less than 18 years of age .

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
patients with covid 19 pneumonia; clinical presentation & outcome of covid 19 pneumonia	Device: CT of the chest; Degree of affection on the lung infected by COVID19

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical evaluation	Patients assessment using CURB 65|(confusion ,urea level, respiratory rate blood pressure,age above 65 years) score 0 or 1 out patient -2 inpatient observation- 3 or more ICU admission.	through study completion, an average of 1 year

Collaborators and Investigators

• Sponsor: Assiut University

Study record dates

Study Major Dates

• Study Start (Anticipated): August 1, 2020
• Primary Completion (Anticipated): August 1, 2021
• Study Completion (Anticipated): September 1, 2021

Study Registration Dates

• First Submitted: July 11, 2020
• First Submitted That Met QC Criteria: July 21, 2020
• First Posted (Actual): July 22, 2020

Study Record Updates

• Last Update Posted (Actual): July 22, 2020
• Last Update Submitted That Met QC Criteria: July 21, 2020
• Last Verified: July 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Lung Diseases; Pneumonia
• Other Study ID Numbers: Presentation of COVID19 in AUH

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No